Memorial Sloan Kettering Cancer Center shared on LinkedIn:
”Memorial Sloan Kettering Cancer Center (MSK) experts, including Cy Wilkins, Jae Park, Karthik Nath, Alina Markova and Roni Shouval presented research related to managing and reducing treatment-related toxicities at the 2023 American Society of Hematology (ASH) Annual Meeting last weekend.
Highlights included factors that predict adverse outcomes with CAR T cell therapy, a promising prophylactic therapy for reducing CAR T cell therapy-related neurotoxicity, a novel treatment for reducing cutaneous graft-versus-host disease (GVHD), and a lack of survival benefit for a platelet-boosting drug in patients with solid tumors who experienced chemotherapy-induced thrombocytopenia (CIT).
Read more about their research here.”